Background: Atopic dermatitis (AD), or atopic eczema, commonly occurs in children and can progress into severe phenotype or atopic march, causing significant impairment in quality of life. To prevent the development of AD, it is important to find early biomarkers to predict the future onset of AD before any clinical manifestations. Methods: Newborns (n=111) with and without family history of atopic diseases (risk group, n=74 control group, n=37) were enrolled in Seoul, Korea. Skin tape strips (STS) were collected from the volar area of the forearm at the age of 2 months before any signs of clinical AD, and children were clinically monitored until they reached 2 years of age to ensure the presence or absence of AD. STS were subjected to lipidomic analyses by the LC-MS/MS and cytokine determination by Meso Scale Discovery (MSD) U-Plex assay. Findings: Overall, 22/74 (29·7%) and 5/37 (13 5%) infants developed AD in the high risk group and the control group, respectively. In the stratum corneum (SC) of future AD children, protein-bound ceramides were significantly decreased, and unsaturated sphingomyelin species and “short-chain” NS- and AS-ceramides were elevated as compared to healthy children. Thymic stromal lymphopoietin and interleukin 13 levels were increased in the SC of future AD subjects at two months of age (by 74 5% and 78·3%, p=0·0022 and p<0 0001, respectively). Univariable logistic regression analysis revealed strong AD predicting power of the combination of type 2 cytokines and dysregulated lipids, with an odds ratio reaching 51·3. Interpretation: Non-invasive STS analysis at two months of age can identify asymptomatic children at risk of future AD development with a high probability. Trial Registration Details: y. The study protocol was registered in the WHO International Clinical Trials Registry Platform (ICTRP). The registration number is KCT0007979. Funding Information: The study was funded by Edelstein Family Chair of Pediatric Allergy-Immunology at National Jewish Health and by Korea Environment Industry and Technology Institute (KEITI) through Environmental Health Action Program, funded by Korea Ministry of Environment (MOE) (2017001360006). Declaration of Interests: EB reports research grants with LEO Pharma and Sanofi Genzyme. EG reports research grants with Sanofi Genzyme. DYML reports consulting with Boehringer-Ingelheim, Evommune, Genetech, LEO Pharma, and Incyte; reports research grant with Sanofi Genzyme. All other authors have nothing to report. Ethics Approval Statement: This study was approved by the institutional review board at Samsung Medical Center in Seoul (IRB No. 2016-12-111), and written informed consent was obtained from all parents prior to participation in this study.